Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood, viscera).  The histone deacetylase inhibitor romidepsin is approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy.  The objective of this analysis was to thoroughly examine the activity of romidepsin within each disease compartment in patients with CTCL.  Romidepsin was shown to have clinical activity across disease compartments and is suitable for use in patients with CTCL having skin involvement only, erythroderma, lymphadenopathy and/or blood involvement.
romidepsin
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood, viscera).  The histone deacetylase inhibitor romidepsin is approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy.  The objective of this analysis was to thoroughly examine the activity of romidepsin within each disease compartment in patients with CTCL.  Romidepsin was shown to have clinical activity across disease compartments and is suitable for use in patients with CTCL having skin involvement only, erythroderma, lymphadenopathy and/or blood involvement.
romidepsin
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood, viscera).  The histone deacetylase inhibitor romidepsin is approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy.  The objective of this analysis was to thoroughly examine the activity of romidepsin within each disease compartment in patients with CTCL.  Romidepsin was shown to have clinical activity across disease compartments and is suitable for use in patients with CTCL having skin involvement only, erythroderma, lymphadenopathy and/or blood involvement.
romidepsin
The histone deacetylase inhibitor romidepsin is approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy. 
US Food and Drug Administration
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood, viscera).  The histone deacetylase inhibitor romidepsin is approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy.  The objective of this analysis was to thoroughly examine the activity of romidepsin within each disease compartment in patients with CTCL.  Romidepsin was shown to have clinical activity across disease compartments and is suitable for use in patients with CTCL having skin involvement only, erythroderma, lymphadenopathy and/or blood involvement.
romidepsin
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood, viscera).  The histone deacetylase inhibitor romidepsin is approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy.  The objective of this analysis was to thoroughly examine the activity of romidepsin within each disease compartment in patients with CTCL.  Romidepsin was shown to have clinical activity across disease compartments and is suitable for use in patients with CTCL having skin involvement only, erythroderma, lymphadenopathy and/or blood involvement.
romidepsin